1-17 of 17
Sara A. Hurvitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TOP-1 Priority: Advancing Biomarker-Driven Patient Selection for the use of ADCs

William R. Gwin, Sara A. Hurvitz
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-25-0166
Published: 17 March 2025
View article titled, TOP-1 Priority: Advancing Biomarker-Driven Patient Selection for the use of ADCs
Open the PDF for TOP-1 Priority: Advancing Biomarker-Driven Patient Selection for the use of ADCs in another window
Journal Articles

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Matthew P. Goetz, Erika P. Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2233–2244.
https://doi.org/10.1158/1078-0432.CCR-22-3573
Published: 15 May 2024
View article titled, Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Open the PDF for Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception

Arielle J. Medford, Beverly Moy, Laura M. Spring, Sara A. Hurvitz, Nicholas C. Turner, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4540–4548.
https://doi.org/10.1158/1078-0432.CCR-23-0757
Published: 14 November 2023
View article titled, Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception
Open the PDF for Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception in another window
Journal Articles

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martín, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1854–1862.
https://doi.org/10.1158/1078-0432.CCR-21-1762
Published: 02 May 2022
View article titled, Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Open the PDF for Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roché, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1383–1390.
https://doi.org/10.1158/1078-0432.CCR-21-2080
Published: 01 April 2022
View article titled, Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer
Open the PDF for Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5818–5827.
https://doi.org/10.1158/1078-0432.CCR-21-1584
Published: 01 November 2021
View article titled, Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View article titled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View article titled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy S. Clark, Amelia Zelnak, Denise A. Yardley, Meghan Karuturi, Tara Sanft, Sibel Blau, Lowell Hart, Cynthia Ma, Hope S. Rugo, Das Purkayastha, Stacy Moulder
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (15): 4177–4185.
https://doi.org/10.1158/1078-0432.CCR-20-2114
Published: 01 August 2021
View article titled, Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Open the PDF for Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) in another window
Includes: Supplementary data
Journal Articles

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

Melody Cobleigh, Denise A. Yardley, Adam M. Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (5): 1105–1113.
https://doi.org/10.1158/1078-0432.CCR-19-2350
Published: 02 March 2020
View article titled, Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
Open the PDF for Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs in another window
Includes: Supplementary data
Journal Articles

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 566–580.
https://doi.org/10.1158/1078-0432.CCR-19-1425
Published: 03 February 2020
View article titled, Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Open the PDF for Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Andrew M. Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2717–2724.
https://doi.org/10.1158/1078-0432.CCR-18-1891
Published: 01 May 2019
View article titled, A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO)
Open the PDF for A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO) in another window
Includes: Supplementary data
Journal Articles

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (8): 2433–2441.
https://doi.org/10.1158/1078-0432.CCR-18-2366
Published: 15 April 2019
View article titled, Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Open the PDF for Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs in another window
Includes: Supplementary data
Journal Articles

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3507–3520.
https://doi.org/10.1158/1078-0432.CCR-13-2769
Published: 01 July 2014
View article titled, Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Open the PDF for Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT in another window
Includes: Supplementary data
Journal Articles

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, Jose M. Perez-Garcia, Sara A. Hurvitz, Nicholas Turner, Hope Rugo, John W. Smith, Stephanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, Alejandro Yovine, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3693–3702.
https://doi.org/10.1158/1078-0432.CCR-13-0190
Published: 30 June 2013
View article titled, Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Open the PDF for Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

Sara A. Hurvitz, David J. Betting, Howard M. Stern, Emmanuel Quinaux, Jeremy Stinson, Somasekar Seshagiri, Ying Zhao, Marc Buyse, John Mackey, Adrian Driga, Sambasivarao Damaraju, Mark X. Sliwkowski, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Omkar Marathe, Dennis J. Slamon, John M. Timmerman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3478–3486.
https://doi.org/10.1158/1078-0432.CCR-11-2294
Published: 14 June 2012
View article titled, Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Open the PDF for Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

Stephen M. Ansell, Sara A. Hurvitz, Patricia A. Koenig, Betsy R. LaPlant, Brian F. Kabat, Donna Fernando, Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6446–6453.
https://doi.org/10.1158/1078-0432.CCR-09-1339
Published: 14 October 2009
View article titled, Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
Open the PDF for Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma in another window
Includes: Supplementary data